Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Data Modul Q3 EBIT Swings to Profit of EUR 1.61 Million; Q3 Revenue Rises 13% to EUR 59.05 Million

Data Modul Q3 EBIT Swings to Profit of EUR 1.61 Million; Q3 Revenue Rises 13% to EUR 59.05 Million

BitgetBitget2026/11/06 07:32
  • Data Modul swung to a third-quarter 2026 operating profit of EUR 1.61 million from a year-earlier loss.
  • Quarterly revenue rose 13% year over year to EUR 59.05 million, while order intake climbed 14% to EUR 58.5 million.
  • Operating cash flow turned positive at EUR 4.85 million for the first nine months of 2026 versus the year-earlier period.
  • Management expects FY26 key financial metrics to remain within its annual forecast, based on current orders and business activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Data Modul AG published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss